参考文献/References:
[1] 赵明日,宇传华.基于年龄-时期-队列模型分析1990-2019年中国归因于高盐饮食的缺血性心脏病疾病负担趋势[J].公共卫生与预防医学, 2024, 35(3): 1-5. ZHAO M R, YU C H. Trend and age-period-cohort anal-ysis of heart disease deaths and DALYattributable to high-salt diets in Chinese residents in 1990-2019[J]. Journal of Public Health and Preventive Medicine, 2024, 35(3): 1-5.
[2] 庞自豪,贾青青,韩博文,等.药物调控mTOR相关信号通路在缺血性心脏病中的研究进展[J].心血管病学进展, 2024, 45(4): 326-331. PANG Z H, JIA Q Q, HAN B W, et al. Drug regulated mTOR related signaling pathways in ischemic heart disease[J]. Advanc-es in Cardiovascular Diseases, 2024, 45(4): 326-331.
[3] 张文斌,向道康,高鲁方,等.血清促炎因子与老年体外循环心脏瓣膜置换患者术后心肌再灌注损伤的相关性[J].中国老年学杂志, 2024, 44(13): 3080-3084. ZHANG W B, XIANG D K, GAO L F, et al. Correla-tion between serum proinflammatory cytokines and myocardial reperfusion injury in elderly patients un-dergoing off-pump heart valve replacement[J]. Chinese Journal of Gerontology, 2024, 44(13): 3080-3084.
[4] 王雨,王楠,朱姗姗,等.外泌体微小RNA-877-5p通过调控Nrf2/HO-1轴诱导铁死亡对肝癌细胞的影响[J].成都医学院学报, 2024, 19(4): 568-572. WANG Y, WANG N, ZHU S S, et al. Effect of exosome miR-877-5p on hepatocellular carcinoma cells induced by Iron mediated cell death through regulation of the Nrf2/HO-1 axis[J]. Journal of Chengdu Medical Col-lege, 2024, 19(4): 568-572.
[5] 刘英存,李飞,黄毅,等.Sestrin2蛋白通过Nrf2/HO-1信号通路保护大鼠心肌细胞缺氧复氧损伤[J].第三军医大学学报, 2020, 42(15): 1536-1542. LIU Y C, LI F, HUANG Y, et al. Sestrin2 protects rat car-diomyocytes from hypoxia-reoxygenation injury through Nrf2/HO-1 signaling pathway[J]. Journal of Third Military Medical University, 2020, 42(15): 1536-1542.
[6] 陈鹏飞,任家孚,阿荣.中医药调控Wnt信号通路治疗心肌缺血再灌注损伤的研究进展[J].现代医药卫生, 2024, 40(15): 2651-2656, 2661. CHEN P F, REN J F, A R. Research progress on the regulation of Wnt signaling pathway by traditional Chinese medicine in the treatment of myocardial isch-emia-reperfusion injury[J]. Journal of Modern Medi-cine & Health, 2024, 40(15): 2651-2656, 2661.
[7] 葛腾,齐鸿飞,姚彬,等.中医药靶向调控线粒体质量控制系统治疗心肌缺血再灌注损伤研究进展[J].中草药, 2024, 55(15): 5331-5341. GE T, QI H F, YAO B, et al. Research progress on tradi-tional Chinese medicine in treatment of myocardial isch-emia reperfusion injury through targeted regulation of mi-tochondrial quality control system[J]. Chinese Traditional and Herbal Drugs, 2024, 55(15): 5331-5341.
[8] 谢锋,张普,段广靖,等.基于HIF/VEGF/eNOS信号通路探究附子-干姜药对抗心肌缺血再灌注损伤作用机制[J].时珍国医国药, 2023, 34(9): 2098-2102. XIE F, ZHANG P, DUAN G J, et al. Study on the mechanism of Fuzi-Ganjiang against myocardial isch-emia-reperfusion in-jury based on HIFα/VEGF/eNOS signaling pathway[J]. Lishizhen Medicine and Materia Medica Research, 2023, 34(9): 2098-2102.
[9] 谢锋,段广靖,王斌,等.基于网络药理学探讨干姜附子汤抗心肌缺血再灌注损伤的作用机制[J].中南药学, 2021, 19(1): 30-38. XIE F, DUAN G J, WANG B, et al. Effect of dried gin-ger-aconite decoction on myocardial ischemia-reperfusion injury and related mechanism based on network pharma-cology[J]. Central South Pharmacy, 2021, 19(1): 30-38.
[10] 国家药典委员会.中华人民共和国药典[M].北京:中国医药科技出版社, 2025: 14, 191. Chinese Pharmacopoeia Commission. The pharmacopoeia of the people’s republic of China [M]. Beijing: China Medical Science and Technology Press, 2025:14,191.
[11] CHEN M T, WANG R Q, LIAO L S, et al. DanShen De-coction targets miR-93-5p to provide protection against MI/RI by regulating the TXNIP/NLRP3/Caspase-1 signal-ing pathway[J].Phytomedicine, 2024, 135: 156225.
[12] HAN D J, WANG F H, JIANG Q J, et al. Enhancing cardioprotection through neutrophil-mediated delivery of 18β-Glycyrrhetinic acid in myocardial ischemia/reperfu-sion injury[J]. Advanced Science, 2024, 11(42): e2406124.
[13] 谢锋.附子干姜配伍抗心肌缺血再灌注损伤作用机制研究[D].陕西咸阳:陕西中医药大学,2021. XIE F. Study on the mechanism of anti-myocardial isch-emia-reperfusion injury of Fuzi-Ganjiang [D].Shaanxi Xianyang: Shaanxi University of Chinese Medicine, 2021.
[14] 李绍麟,张曙影.外泌体调控铁死亡:心血管疾病治疗的新思路[J].心血管康复医学杂志,2024,33(4):512-515. LI S L, ZHANG S Y. Exosome regulation of ferro-ptosis:a new idea for the treatment of cardiovascular diseases[J]. Chinese Journal of Cardiovascular Rehabil-itation Medicine, 2024, 33(4): 512-515.
[15] 周健慧,陆峰.铁死亡在中医药治疗心肌肥厚中的研究进展[J].中西医结合心脑血管病杂志, 2024,22(13): 2370-2374. ZHOU J H, LU F. Research progress on the role of ferroptosis in the treatment of cardiac hypertrophy with Traditional Chinese Medicine[J]. Chinese Journal of Integrative Medicine on Cardio/Cerebrovascular Disease, 2024, 22(13): 2370-2374.
[16] XU S J, WU B X, ZHONG B Y, et al. Naringenin alleviates myocardial ischemia/reperfusion injury by regulating the nu-clear factor-erythroid factor 2-related factor 2 (Nrf2) /System Xc-/ glutathione peroxidase 4 (GPX4) axis to inhibit ferropto-sis[J]. Bioengineered, 2021, 12(2): 10924-10934.
[17] YANG T, LIU H Q, YANG C B, et al. Galangin attenu-ates myocardial ischemic reperfusion-induced ferropto-sis by targeting Nrf2/Gpx4 signaling pathway [J]. Drug Design, Development & Therapy, 2023, 17: 2495.
[18] FANG X X, WANG H, HAN D, et al. Ferroptosis as a target for protection against cardiomyopathy[J]. Pro-ceedings of the National Academy of Sciences of the United States of America, 2019, 116(7): 2672-2680.
[19] 张恒,袁莉,王佩,等.血管生成素样蛋白2(ANGPTL2)对大鼠局灶性脑缺血/再灌注损伤的炎症保护机制研究[J].现代检验医学杂志, 2019, 34(6): 32-35, 46. ZHANG H, YUAN L, WANG P, et al. Study on the inflammatory protective mechanism of angiogenin-like protein 2 (ANGPTL2) on focal cerebral ischemia/reper-fusion injury in rats[J]. Journal of Modern Laboratory Medicine, 2019, 34(6): 32-35, 46.
[20] 高立华,张旭华.骨髓间充质干细胞对缺血再灌注大鼠急性心肌梗死保护作用研究[J].现代检验医学杂志,2013,28(6):78-81. GAO L H, ZHANG X H. Effect of bone marrow-de-rived stem cells on acute myocardial infarction in isch-emia-reperfusion rats[J]. Journal of Modern Laboratory Medicine, 2013, 28(6): 78-81.
[21] 杨鑫,王晓蕾,杨孟丽,等.星状神经节阻滞对大鼠心肌缺血再灌注损伤的影响[J].新乡医学院学报, 2023, 40(8): 707-711. YANG X, WANG X L, YANG M L, et al. Effect of stel-late ganglion block on myocardial ischemia-reperfusion injury in rats[J]. Journal of Xinxiang Medical Universi-ty, 2023, 40(8): 707-711.
[22] 黄毅,王琮翰.miR-330-5p调控Nox4对缺氧复氧大鼠胚胎心肌细胞损伤影响的实验研究[J].现代检验医学杂志, 2024, 39(6): 48-53, 83. HUANG Y, WANG C H. Experimental study on the effect of miR-330-5p regulated Nox4 on the damage of fetal car-diomyocytes in hypoxic-reoxygenated rats[J]. Journal of Modern Laboratory Medicine, 2024, 39(6): 48-53, 83.